H.R.2315 - Preserving Access to Orphan Drugs Act of 2013113th Congress (2013-2014)
|Sponsor:||Rep. Gerlach, Jim [R-PA-6] (Introduced 06/11/2013)|
|Committees:||House - Energy and Commerce; Ways and Means|
|Latest Action:||House - 07/25/2013 Referred to House Energy and Commerce (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.2315 — 113th Congress (2013-2014)All Information (Except Text)
Introduced in House (06/11/2013)
Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.
Makes this Act effective as if included in PPACA.